baber/WOPTO huggingface dataset:
Patent NZ-504253-A (NZ)
Title: Computerized dispute resolution system and method
Inventor: BURCHETTA JAMES D
IPC: G06Q50/18
Filed: 1999-08-06
Abstract: A computerized system for automated dispute resolution through an Intranet website via the Internet or other communications linkage for communicating and processing a series of demands to satisfy a claim made by or on behalf of a claimant or other person involved in a dispute with at least one other person, such as a defendant, his insurer, or other sponsor, and a series of offers to settle the claim through at least one central processing unit including operation system software for controlling the central processing unit is disclosed. Preferably, the system also allows for the collection, processing, and dissemination of settlement data generated from settlements through the operation of the system for use by sponsors and claimants in establishing the settlement value of future cases. Also disclosed is a method for communicating and processing a series of demands and a series of offers through the system.
Patent NZ-505701-A (NZ)
Title: Activating pin
Inventor: VAN DER BLOM NICOLAAS
IPC: B60S5/04
Filed: 1997-05-14
Abstract: The invention concerns an activation pin for a valve connector for connecting to an inflation valve. The connector comprises of a housing that is connected to the pressure source. The housing sits over the pressure source through its coupling hole, which has a central axis (337).  The activation pin conducts gaseous media between the cylinder (302) and the pressure source by manipulating the piston valve position (304). Also, the activation pin is arranged to engage with a central spring-force operated core pin of the inflation valve.
Patent NZ-507190-A (NZ)
Title: Incorporation of active substances in carrier matrixes wherein an emulsion is contacted with a fluid gas using an anti-solvent technique
Inventor: ANDERSSON MARIE-LOUISE
IPC: A61K38/00
Filed: 1999-04-09
Abstract: A process for the preparation of a formulation, which comprises an active substance or active substances, associated with a carrier.  The process involves preparing an emulsion by mixing a liquid, non-aqueous phase and a liquid, aqueous phase, the aqueous phase comprising the active substance or substances and the carrier being present in at least one of the phases.  The emulsion is contacted with a fluid gas using an anti-solvent technique, and units freed of the liquid phase are collected.
Patent NZ-507698-A (NZ)
Title: Stearable tandem roller
Inventor: OKABE MIKIO
IPC: E01C19/28
Filed: 2000-10-20
Abstract: A hand guided vibrating roller has front R1 and rear R2 roller wheels generally arranged in parallel and supporting a body 30.  A hydraulic pump P is mounted on the body and drives the hydraulic motors M1 and M2 for driving the respective rollers and mounted within the rollers.  A steering handle 40 extends from the rear portion of the body and at least one of the rollers, the front roller being shown, is supported in a frame 10 that is freely rotatable around a vertical axis 50a so that the actuator 55, 56 can steer the front roller in accordance with commands generated at the holding end 70 of the handle.
Patent NZ-511010-A (NZ)
Title: Sustained release pharmaceutical composition containing fluvastatin
Inventor: SHAH RAJEN
IPC: A61K31/22
Filed: 1999-10-12
Abstract: A sustained-release pharmaceutical compositions for the avoidance of the burst effect comprises: fluvastatin or a pharmaceutically acceptable salt thereof; hydroxypropyl methyl cellulose and a non-ionic, hydrophilic polymer selected from hydroxyethyl cellulose having a number average molecular weight ranging from 90,000 to 1,300,000, hydroxypropyl cellulose having a number average molecular weight of 370,000 to 1,500,000, and poly(ethylene oxide) having a number average molecular weight ranging from 100,000 to 500,000.
Patent NZ-513637-A (NZ)
Title: Nanoscale electronic devices & fabrication methods
Inventor: SCHMELZER JUERN
IPC: B82B3/00
Filed: 2001-08-20
Abstract: A method of forming at least a single conducting chain of nanoparticles between a number of contacts on a substrate comprises: a. forming the contacts on the substrate; b. preparing a plurality of nanoparticles; c. depositing of a plurality of nanoparticles on the substrate at least in the region between the contacts and d(i) monitoring the conduction between the contacts or simultaneously between another set of similar contacts and ceasing deposition at or near to the onset of conduction to thereby form a conducting chain of nanoparticles between the contacts, or carrying out the deposition of a predetermined time calculated to cease the deposition of particles at or near to the onset of conduction between the contacts and/or d(ii) modifying the substrate surface or taking advantage of one or more pre-existing topographical feature(s) so as to cause the nanoparticles deposited in the region of the modification or topographical feature.
Patent NZ-514552-A (NZ)
Title: NR2B subunit selective N-methyl-D-aspartate (NMDA) receptor antagonists for treating or preventing neurological damage and pain
Inventor: CHENARD BERTRAND LEO
IPC: A61K31/439
Filed: 2001-10-01
Abstract: Described herein is a method of inhibiting in a mammal neurological damage resulting from impairment of glucose and/or oxygen supply to the brain, which method comprises administering to the mammal prior to the impairment of glucose and/or oxygen supply to the brain an amount of an NR2B subunit selective NMDA antagonist, which amount is effective in inhibiting neurological damage. Also described is a method of preventing primary hyperalgesia, secondary hyperalgesia, primary allodynia, secondary allodynia, or other pain caused by central sensitization, in a mammal, which method comprises administering to the mammal, prior to affliction with said pain, an amount of an NR2B subunit selective NMDA antagonist, which amount is effective in preventing said pain.
Patent NZ-514576-A (NZ)
Title: Substituted 3-cyano-[1.7], [1.5], and [1.8]- naphthyridine inhibitors of tyrosine kinases
Inventor: WISSNER ALLAN
IPC: C07D471/04
Filed: 2000-04-18
Abstract: This invention provides compounds of formula (I), wherein A'' is a diavalent moiety selected from the groups (II, III, IV) which are useful as inhibitors of protein tyrosine kinase.
Patent NZ-523053-A (NZ)
Title: Protein purification by ion exchange chromatography
Inventor: BASEY CAROL D
IPC: C07K16/44
Filed: 2002-12-09
Abstract: A method for purifying an antibody from a composition comprising the antibody and a contaminant which method comprises loading the composition onto a cation exchange resin wherein the amount of antibody loaded on to the cation exchange resin is from 20 mg to about 35mg of the antibody per mL of cation exchange resin. The purified antibody from the above method is also discussed.
Patent NZ-525092-A (NZ)
Title: A thermoplastic compositions comprising a copolymer and a multi-staged sequentially-polymerized impact modifer polymer
Inventor: CRABB CHARLES CLARENCE
IPC: B32B27/30
Filed: 2003-04-01
Abstract: Disclosed herein is an improved weatherable thermoplastic composition, wherein the composition comprises a copolymer of an alkyl acrylate or alkyl methacrylate and poly(methyl)methacrylate and a multi-stage, sequentially-polymerized impact modifier polymer; the copolymer is characterized by greater than 15 weight percent alkyl acrylate content; the multi-stage, sequentially-polymerized impact modifier is characterized by an elastomer stage, which is 55 percent by weight or greater of the impact modifier composition and is minimally crosslinked. This thermoplastic composition can be used in a wide range of film, sheet, or molded applications.
Patent NZ-525676-A (NZ)
Title: Processes and compositions for water treatment
Inventor: MCCONCHIE DAVID
IPC: C02F1/52
Filed: 2001-10-26
Abstract: A process for treating acidic water containing dissolved inorganic substances comprising the steps of: (i) adding a pH-raising additive in an amount of sufficient to increase the pH of the water to a predetermined value; and (ii) adding neutralised bauxite refinery residue to the water in an amount sufficient to decrease the concentration of at least one of said inorganic substances in said water to below a predetermined level; wherein said neutralised bauxite refinery residue is red mud that has been treated with seawater, saline ground water of other water containing sufficient calcium and magnesium ions to react with substantially all of the hydroxide, carbonate, fluoride and oxalate ions present in the red mud, and for a time sufficient for the red mud to exhibit a reaction pH of less than 10.5, in a standard soil test when 1 part by weight of the neutralised red mud is mixed with 5 parts by weight of distilled or deionised water; a composition comprising a mixture of the neutralised bauxite refinery residue and a water treating additive; and a process for neutralising red mud, comprising mixing red mud with an aqueous treating solution containing a base amount and a treating amount of calcium ions and a base amount and a treating amount of magnesium ions, for a time sufficient to produce an at least partially neutralised red mud and a spent aqueous solution wherein: the partially neutralised red mud has a reaction pH when one part by weight is mixed with 5 parts by weight of deionised or distilled water, of a pH less than 10.5; the base amounts of calcium and magnesium ions are 8mmol/L and 12mmol/L of the total volume of the treating solution and red mud respectively; and the treating amount of calcium ions and magnesium ions are at least 25mmol and 400mmol per mole of total alkalinity of the red mud expressed as calcium carbonate equivalent alkalinity, provided that the aqueous treating solution is other than seawater.
Patent NZ-527048-A (NZ)
Title: Crystalline forms of atorvastatin
Inventor: VAN DER SCHAAF PAUL ADRIAAN
IPC: A61P43/00
Filed: 2001-12-19
Abstract: A crystalline polymorph of [R-(R*,R*)]-2-(4-fluorophenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (atorvastatin calcium) exhibits a characteristic X-ray powder diffraction pattern with characteristic peaks expressed in d-values (A) at a) 27.9 (s), 20.9 (w), 18.9 (w), 16.1 (w), 11.1 (m), 10.5 (m), 9.1 (m), 5.53 (m), 5.07 (w), 4.77 (vw), 4.55 (m), 4.13 (w), 3.69 (w); b) 31.0 (vw), 18.6 (m), 17.0 (w), 15.3 (vw), 12.8 (w), 11. 2 (m), 9.6 (s), 9.3 (w), 8.6 (w), 7.4 (m), 6.5 (vw), 6. 2 (vw), 5.47 (w), 5.21 (m), 4.64 (vs), 4.46 (s), 4.14 (m), 3.97 (m), 3.74 (m), 3.62 (vw), 3.38 (w), 3.10 (m); c) 27.9 (m), 17.0 (m), 14.2 (w), 12.1 (vs), 10.1 (s), 8.6 (m), 7.1 (m), 6.1 (vw), 5.27 (m), 4.89 (m), 4.68 (m), 4.46 (m), 4.22 (m), 3.90 (w), 3.70 (w), 2.36 (vw); d) 28.1 (m), 17.2 (m), 14.0 (vw), 12.3 (s), 10.4(s), 8.6 (m), 7.5 (w), 7.0 (m), 5.28 (m), 4.88 (m), 4.55 (m), 4.27 (m), 3.88 (vw), 3.73 (m); e) 28.8 (m), 24.0 (m), 17.1 (m), 11.3 (s), 9.8 (vw), 8.3 (w), 7.7 (vw), 6.9 (vw), 5.64 (vw), 5.21 (w), 4.59 (m), 4.39 (w), 4.16 (w), 3.70 (w); f) 33.7 (w), 31.0 (m), 16.9 (m), 10.3 (s), 7.7 (w), 6.4 (vw), 4.84 (s) and g) 26.8 (s), 9.4 (w), 4.6 (m) wherein (s) = strong intensity; (m) = medium intensity; (w) = weak intensity. Atorvastatin calcium is an orally-active hypocholesterolaemic, a liver-selectiveHMG-CoA reductase inhibitor.
Patent NZ-528999-A (NZ)
Title: An assay for detecting inhibitors of the enzyme myeloperoxidase and as a diagnostic test
Inventor: KETTLE ANTHONY
IPC: C12N9/08
Filed: 2002-05-06
Abstract: A method for identifying inhibitors of myeloperoxidase (MPO) comprises reacting MPO with hydrogen peroxide and a chloride source to generate hypochlorous acid in the presence of a potential inhibitor of MPO, reacting any formed hypochlorous acid with a suitable amine to fork the corresponding chloramines. Any unreacted hydrogen peroxide is the optionally removed. Any formed chloramine is reacted with a suitable detector molecule in the presence of iodide to form oxidizes detector molecule. The amount of formed oxidized detector molecule is determined by measuring the absorbance or fluorescence at a suitable wavelength and then identifying as inhibitors of MPO those compounds which cause the amount of formed oxidized detector molecule to be decreased. The method can also be used in a diagnostic test for myeloperoxidase activity.
Patent NZ-535218-A (NZ)
Title: Ground opening apparatus for agricultural implement
Inventor: TAEGE BRIAN STEWART
Filed: 2005-03-09
Abstract: Ground breaking apparatus which includes at least one disc which has a central hole and which is attached to a mounting, wherein said mounting includes; a first mounting arm which at a first location is pivoted to a mounting means and at a second location is connected to the disc such that the disc is free to rotate about its central hole, said first location being spaced apart from said second location; and at least one S-Tyne spring which is mounted upon said mounting means and which is arranged to bias said mounting arm and said disc into engagement with the ground.
Patent NZ-537955-A (NZ)
Title: Injectable depot compositions and uses thereof
Inventor: CHEN GUOHUA
IPC: A61K9/14
Filed: 2002-11-14
Abstract: Injectable depot compositions are disclosed that include a biodegradable, biocompatible lactic acid-based polymer, a solvent having a miscibility in water of less than or equal to 7 wt. % at 25 DEG C, in an amount effective to plasticize the polymer and form a gel therewith, a thixotropic agent, and a beneficial agent. The solvent comprises an aromatic alcohol, an ester of an aromatic acid, an aromatic ketone, or mixtures thereof. The compositions have substantially improved the shear thinning behaviour and reduced injection force, rendering the compositions readily implanted beneath a patient's body surface by injection.
Patent NZ-538323-A (NZ)
Title: Production of isoflavone derivatives
Inventor: HEATON ANDREW
IPC: C07D311/36
Filed: 2000-02-15
Abstract: Methods for the hydrogenation of isoflavones are disclosed, which provide access to workable quantities of isoflavan-4-ols, isoflav-3-enes, and isoflavans. The isoflavone derivatives of formula (II), formula (III) and formula (IV) can be obtained in high purity and in near quantitative yields whilst employing pharmaceutically acceptable reagents and solvents. (62) Divided out of 527700
Patent NZ-545607-A (NZ)
Title: Electrical power distribution conduit and connector able to be inserted at any point with rotation to connect
Inventor: JONG CHOON
IPC: H01R13/453
Filed: 2004-01-21
Abstract: An improved electrical power distribution apparatus is provided which includes a conduit containing at least one elongate conductor (4126, 4128). The conduit has an opening (4154) through which a connector is able to be inserted to connect electrically with the conductor (4126, 4128). A plurality of conductive members (5100) disposed between the opening (4154) and the conductor (4126, 4128), and a plurality of resilient support members (5200) are provided such that each conductive member (5100) is separately supported by a respective support member (5200) and displaceable by a connector to provide access to the conductor. An improved power supply connector for use with the power distribution apparatus is also disclosed.
Patent NZ-546230-A (NZ)
Title: An electronic controller for an engine
Inventor: LODA DAVID C
Filed: 2004-10-04
Abstract: An electronic controller (62) for an engine (50) is disclosed. The electronic controller (62) includes a closed architecture section (66) for controlling and monitoring the engine (50), and an open architecture section (68). The open architecture section (68) includes a microserver (80) for generating a wireless system adapted to connect to the internet. A security connection (70) is provided between the closed architecture section (66) and the open architecture section (68).
Patent NZ-550200-A (NZ)
Title: A method of lysing a blood clot comprising administering a fibrinolytic agent selected from fibrolase and NAT to a non-human animal
Inventor: KENDRICK BRENT S
IPC: A61K9/19
Filed: 2000-09-29
Abstract: Disclosed is a method of lysing a blood clot in a non-human mammal comprising administering a pharmaceutical composition to said non-human mammal, wherein said composition comprises a metalloproteinase fibrinolytic agent selected from the group consisting of fibrolase and NAT, a zinc stabiliser and optionally, a bulking agent, in a pharmaceutically acceptable buffer. (62) Divided Out of 540967
Patent NZ-550320-A (NZ)
Title: Compositions capable of facilitating penetration across a biological barrier
Inventor: BEN-SASSON SHMUEL A
IPC: A61K38/34
Filed: 2005-04-14
Abstract: Disclosed is a pharmaceutical composition comprising a suspension of a therapeutically effective amount of an effector such as, at least one salt of a fatty acid selected from sodium octanoate, sodium decanoate or sodium dodecanoate, and a hydrophobic medium; wherein the effector and the salt of the fatty acid are suspended in the hydrophobic medium. The disclosure also relates to use of the composition in the manufacture of a medicament for the treatment of metabolic disorders and a method of producing said composition.
Patent NZ-553139-A (NZ)
Title: Materials and methods for the modification of plant lignin content
Inventor: BLOKSBERG LEONARD NATHAN
IPC: C12N/
Filed: 1999-10-06
Abstract: An isolated polynucleotide encoding coenzyme A by4-coumarate:CoA ligase (4CL), isolated primers for amplifying said polynucleotide, transformed cells transformed by a genetic construct comprising the polynucleotide, and a protein encoded by the polynucleotide are disclosed. Plant lignin content, lignin composition and lignin structure can be modified by stably incorporating into the genome of a plant the polynucleotide.
Patent NZ-562243-A (NZ)
Title: Applying time-varying current to at least two parallel heaters with equal voltage applied to ends of the heaters to inhibit current leakage
Inventor: VINEGAR HAROLD J
IPC: E21B36/04
Filed: 2006-04-21
Abstract: A system for heating a subsurface formation is disclosed. The system includes a number of elongated resistance heaters located in openings in the formation. At least two of the heaters are parallel to each other for at least a portion of the lengths of the heaters, and at least two of the heaters have first end portions in a first location on the surface and second end portions in a second location on the surface. The system also includes a source of time-varying current configured to apply time-varying current to at least two of the heaters. The first end portions of at least two heaters are configured to have substantially the same voltage applied to them, and the second end portions of at least two heaters are configured to have substantially the same voltage applied to them. The system is configured to inhibit current leakage between heaters in the formation.
Patent NZ-564223-A (NZ)
Title: Diarylhydantoin compounds for treating hormone refractory prostate cancer
Inventor: SAWYERS CHARLES L
IPC: A61K31/4166
Filed: 2006-03-29
Abstract: Disclosed are the three diphenylhydantoin compounds of the pictured formulas. Also disclosed the use of the compounds to treat a hyperproliferative disorder such as hormone refractory prostate cancer.
Patent NZ-566020-A (NZ)
Title: Prion-specific peptoid reagents
Inventor: PERETEZ DAVID
IPC: A23L7/104
Filed: 2006-09-08
Abstract: Disclosed is an isolated, synthetic or purified peptoid reagent capable of interacting preferentially with a pathogenic form of a conformational disease protein as compared to a nonpathogenic form of the conformational disease protein, the peptoid reagent having a formula of: Xa-(Q)n-Xb) wherein: -(Q)n- defines a peptoid region comprising a sequence selected from the group consisting of: SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, and SEQ ID NO: 240 or a variant of any one of said sequences wherein a single amino acid residue thereof is substituted such that said peptoid region comprises N-(4-aminobutyl) glycine at position 2 or (S)-N-(1-phenylethyl) glycine at position 2 or N-(4-aminobutyl) glycine at position 3 or N-(4-guanidinobutyl) glycine at position 3 or N-(4-aminobutyl) glycine at position 4 or (S)-N-(1-phenylethyl) glycine at position 4 or N-benzyl glycine at position 4 or N-(4-aminobutyl) glycine at position 5 or (S)-N-(1-phenylethyl) glycine at position 5 or (S)-N-(1-phenylethyl) glycine at position 6 or N-benzyl glycine at position 6; Xa is absent or selected from the group consisting of: H, (C 1 -C6)alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, (C1-C6)acyl, amino(C1-6)acyl, an amino acid, an amino protecting group, and a polypeptide of 2 to 100 amino acids in length, and wherein Xb if present is optionally substituted by a conjugate moiety that is optionally attached through a linker moiety; and Xb is absent or an amino acid that is optionally substituted by a conjugate moiety that is optionally attached through a linker moiety.
Patent NZ-570888-A (NZ)
Title: A disengageable spindle drive for a tap
Inventor: AMMUNSON DAVID JOHN
IPC: F16L37/086
Filed: 2007-01-30
Abstract: A disengageable shaft drive arrangement includes: a drive member; a driven shaft; and a disengageable drive mechanism to connect the shaft and drive member. The mechanism includes one or more engagement recesses and one or more engagement members where each engagement member is adapted to cooperate with the engagement recess. A disengagement member may disengage the or each engagement member from the engagement recess with which it is engaged where each engagement member is magnetically or gravitationally biased.
Patent NZ-575652-A (NZ)
Title: Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
Inventor: VERNIER JEAN-MICHEL
IPC: A61K31/47
Filed: 2007-08-22
Abstract: The disclosure relates to a compound of formula (IA) which are affective for the opening of, or otherwise modulating, voltage-gated potassium channels, wherein the variable X = O or S; Y is O or S; q = 1 or 0; and the other substituents are as defined in the specification. These compounds are potentially useful for the treatment and prevention of diseases and disorders which are affected by activation or modulation of potassium ion channels. One such condition is seizure disorders.
Patent NZ-578514-A (NZ)
Title: Fluid filter system with filters of three different density materials and method
Inventor: GAJJAR NEKHEEL
IPC: B01D39/00
Filed: 2009-07-21
Abstract: A fluid filter 5 comprises two filter layers 198, 205 coupled to each other, with the first filter layer 198 comprising alternating strips of a first and second filter material where the density of the second filter material 202 is greater than that of the first filter material 200. The second filter layer 205 comprises a third filter material 204 with a greater density than the second filter material 202.
Patent NZ-587863-A (NZ)
Title: Method for purifcation and seperation of biological molecules (e.g. DNA or proteins or complexes of) by reversing electrophoresis polarity
Inventor: MATHERS WILLIAM D
IPC: G01N27/447
Filed: 2009-03-02
Abstract: Discloses a method for electrophoretic separation of free biomolecules from molecular complexes comprising biomolecules of interest, wherein inhomogeneity (size differences) in the molecular complexes is masked, the method comprising: (i) electrophoresing a sample comprising free biomolecules and the molecular complexes in an electrophoresis gel for a period of time sufficient for the free biomolecules to elute off a distal end of the electrophoresis gel, wherein the molecular complexes comprising the biomolecules of interest are retained in the electrophoresis gel; (ii) reversing direction of electrophoresis and electrophoresing the sample for a period of time sufficient for the molecular complexes of bound biomolecules of interest to elute from a proximal end of the electrophoresis gel The method finds application in separation of molecular complexes e.g. DNA:protein complexes in a suitable gel electrophoresis system.